<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159597">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01694394</url>
  </required_header>
  <id_info>
    <org_study_id>ASSERT-II</org_study_id>
    <nct_id>NCT01694394</nct_id>
  </id_info>
  <brief_title>Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor</brief_title>
  <acronym>ASSERT-II</acronym>
  <official_title>Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor in Patient With Cardiovascular Risk Factors (ASSERT-II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research  (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine the rate of detection of sub-clinical
      atrial fibrillation (≥ 5 minutes)within an average of 12 months following implant of the St.
      Jude Medical Confirm(R) Implantable Cardiac Monitor in patients with known cardiovascular
      risk factors and left atrial enlargement, but without prior AF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title of Study Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac
      Monitor in Patients with Cardiovascular Risk Factors (ASSERT-II) Short Title ASSERT-II Study
      Sponsor Population Health Research Institute (Grant in Aid from St. Jude Medical, Inc.)
      Principal Investigators Dr. J. Healey, Dr. S. Connolly, Dr. M. Alings Central Coordinating
      Centre Population Health Research Institute Recruitment and Participating Clinical Sites 250
      patients from approximately 30 Sites Phase/Regulatory Status Phase IV - Cohort Study
      Hypothesis Among elderly patients with cardiovascular risk factors and a left atrial
      diameter ≥ 4.4 cm, but without prior clinical AF, an implanted continuous ECG monitor (St.
      Jude Medical Confirm® Implantable Cardiac Monitor) will detect subclinical AF (≥ 5 minutes
      in duration) in 12% or more of patients during an average follow-up of 12 months.

      Study Objectives

      Primary Objectives:

      1. To determine the rate of detection of sub-clinical atrial AF (≥ 5 minutes) within an
      average of 12 months following implant of the St. Jude Medical Confirm® Implantable Cardiac
      Monitor in patients with known cardiovascular risk factors and left atrial enlargement, but
      without prior AF.

      Secondary Objectives

        1. To determine if the incidence of sub-clinical AF is higher among patients whose left
           atrial volume is above the median value observed in this study.

        2. To determine the relationship between left atrial volume (continuous variable) and the
           risk of sub-clinical AF.

        3. To evaluate other potential predictors of sub-acute AF in this population including:
           baseline troponin-T, baseline NT-pro-BNP as well as clinical and other
           echocardiographic parameters.

        4. To develop a preliminary economic analysis to evaluate the potential cost-effectiveness
           of screening this patient population with an Implantable Cardiac Monitor as a means of
           preventing stroke.

      Study Design Cohort study to determine the prevalence of sub-clinical AF in an elderly
      population with common cardiovascular risk factors, such as hypertension and diabetes.
      Patients with echocardiographic evidence of atrial enlargement will be enrolled and have the
      St. Jude Medical Confirm® Implantable Cardiac Monitor (Confirm® ICM) subcutaneously
      implanted. To reduce costs, in most cases the implant will be done in conjunction with other
      planned surgery or heart catheterization.

      PHRI: CONFIDENTIAL Final Version 2.0:2012-06-18 Page 4 of 24 Participants/Study Duration
      Total of 250 participants will be enrolled over 16 months. The last patient enrolled will
      have 9 months of follow-up, for a total study duration of approximately 25 months. Clinic
      visits will occur at enrolment and months 3, 6 and 9. A final visit will take place at 18
      months of follow-up, or after the last patient enrolled has been followed for 9 months
      (whichever comes first).

      Study Population Patients with known cardiovascular risk factors and left atrial
      enlargement, with no prior documented AF.

      Intervention St. Jude Medical Confirm® Implantable Cardiac Monitor (Confirm® ICM) Enrollment
      and Follow-up Eligible and consenting patients will be enrolled and have the Confirm® ICM
      implanted. The implant may take place in conjunction with pre-planned non-cardiac surgery,
      heart catheterization, or as a stand-alone procedure. Follow-up visits will occur at month
      3, 6 and 9. A final visit will take place at 18 months of follow-up, or after the last
      patient enrolled has been followed for 9 months (whichever comes first).

      Assessment of Outcome Events An independent central adjudication committee comprised of
      arrhythmia experts will evaluate device-detected AF episodes.

      Statistical Methodology Determine the incidence of sub-clinical atrial AF (≥ 5 minutes)
      using the Confirm® ICM.

      Date of Protocol June 18, 2012
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>First atrial fibrillation episode at least 5 minutes in duration</measure>
    <time_frame>over maximum follow-up of 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>incidence of atrial fibrillation detected by continuous monitoring by an implantable cardiac monitor</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
    <description>Single arm cohort will receive Implantable Cardiac Monitor for continuous monitoring over the study follow-up period to determine incidence of sub-clinical atrial fibrillation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable Cardiac Monitor (Confirm(R)ICM model 2102)</intervention_name>
    <arm_group_label>Cohort</arm_group_label>
    <other_name>St. Jude Medical Confirm(R)ICM model 2102</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood will be collected for NT-ProBNP and hs-Troponin-T
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at increased risk of atrial fibrillation and cardiovascular events but without
        prior history of atrial fibrillation or implanted pacemaker or defibrillator
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients will be eligible for inclusion if they meet both of the following:

          1. Age ≥ 65, plus:

               -  CHA2DS2-VASc score ≥ 2 Or

               -  Obstructive sleep apnea (documented by polysomnography, ambulatory oximetry,
                  positive Berlin Questionnaire or requiring the use of CPAP/BiPAP) Or

               -  BMI &gt; 30

          2. Echocardiographic or biochemical evidence of increased risk of AF:

               -  Left atrial enlargement on a clinical echocardiography at any time prior to
                  enrollment ( defined as LA volume ≥ 58 ml or LA diameter of ≥ 4.4 cm) Or

               -  Serum NT-ProBNP ≥ 290 pg/mL Exclusion Criteria

        1. Previously documented history of atrial fibrillation or atrial flutter 2. Current
        chronic treatment with oral anticoagulation (i.e. those on peri-operative prophylaxis
        would be eligible) 3. Patient with implanted pacemaker or defibrillator with an atrial
        lead 4. Definitive plan for cardiac surgery in the next 6 months (patients who are having
        coronary angiography with a possibility of cardiac surgery are still eligible)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Healey, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stuart Connolly, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Alings, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Working group Cardiovascular research Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather J Beresh, M.Sc.</last_name>
    <phone>905-527-4322</phone>
    <phone_ext>40351</phone_ext>
    <email>heather.beresh@phri.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ellison Themeles, M.Sc.</last_name>
    <phone>905-527-4322</phone>
    <phone_ext>40488</phone_ext>
    <email>ellison.themeles@phri.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carol Kenney</last_name>
      <phone>403-944-4286</phone>
      <email>Carol.Kenney@albertahealthservices.ca</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Wright</last_name>
      <phone>403-944-4286</phone>
      <email>Michelle.Wright@albertahealthservices.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Michael D Hill, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Boniface Hospital</name>
      <address>
        <city>Winnepeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Polson</last_name>
      <phone>204-258-1267</phone>
      <email>JMPolson@sbgh.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Colette Seifer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences - Electrophysiology Clinic</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victoria Malcolm</last_name>
      <phone>905-527-4322</phone>
      <phone_ext>44506</phone_ext>
      <email>malcolmv@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Carlos Morillo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences - Interventional Cardiology</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chris Beck</last_name>
      <phone>905-527-4322</phone>
      <phone_ext>44152</phone_ext>
      <email>beckc@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Shamir Mehta, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences - Perioperative Ischemia Research Group</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Krysten Gregus</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>67177</phone_ext>
      <email>gregus@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Philip J Devereaux, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Center University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathy Blackler</last_name>
      <phone>519-663-3746</phone>
      <email>kblackle@uwo.ca</email>
    </contact>
    <investigator>
      <last_name>Peter Leong-Sit, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southlake Regional HealthCare</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annette Nath</last_name>
      <phone>905-953-7917</phone>
      <email>ANATH@southlakeregional.org</email>
    </contact>
    <investigator>
      <last_name>Atul Verma, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>613-761-5208</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan McClinton</last_name>
      <phone>613-761-5208</phone>
      <email>smcclinton@ottawaheart.ca</email>
    </contact>
    <contact_backup>
      <last_name>Rochelle Fleming</last_name>
      <phone>613-798-5555</phone>
      <phone_ext>18608</phone_ext>
      <email>rfleming@ottawaheart.ca</email>
    </contact_backup>
    <investigator>
      <last_name>David Birnie, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Davies, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kawartha Cardiology Clinic</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jen Fraser</last_name>
      <phone>705-743-3555</phone>
      <email>jfraser@vhn.ca</email>
    </contact>
    <investigator>
      <last_name>William Hughes, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Sciences North</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cindy Bobbie</last_name>
      <phone>705-523-7100</phone>
      <phone_ext>2488</phone_ext>
      <email>cbobbie@hsnsudbury.ca</email>
    </contact>
    <investigator>
      <last_name>Atilio Costa-Vitali, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ann Hill</last_name>
      <phone>416-340-4339</phone>
      <email>ann.hill@uhn.on.ca</email>
    </contact>
    <investigator>
      <last_name>Andrew Ha, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Doug Cameron, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H9S 1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fiorella Rafti, Ph.D</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>42926</phone_ext>
      <email>fiorella.rafti@mail.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Vidal Essebag, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Quebec (Hopital Laval)</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francois Philippon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raymond Labbe, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 26, 2012</lastchanged_date>
  <firstreceived_date>September 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Population Health Research Institute</investigator_affiliation>
    <investigator_full_name>Jeff Healey</investigator_full_name>
    <investigator_title>Associate Professor, McMaster University</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>implantable cardiac monitor</keyword>
  <keyword>left atrial enlargement</keyword>
  <keyword>CHA2DS2 VASc Score</keyword>
  <keyword>cardiovascular risk</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
